Apollo Care Semaglutide Vials Recalled for Particulate Matter

Source: FDA · United States

Areazine synthesizes this FDA recall directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.

Apollo Care, LLC is recalling 250 vials of semaglutide 7.5mg/glycine due to particulate matter contamination.

What this FDA recall tells you, and what most readers miss

This notice was issued by FDA on August 25, 2026 and geographically references United States. The FDA classifies this as a Class II recall, with the stated reason "Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material", distributed nationwide within the u.s. FDA recall classes run from I (reasonable probability of serious harm) to III (unlikely to cause harm), so the class number is the fastest way to gauge severity here. The category it belongs to - FDA Recalls - determines the consumer-protection framework behind it, which shapes what remedies (refunds, replacements, repairs, or the recall itself) are available to affected consumers and which agency holds statutory responsibility for enforcement.

It is tempting to skim, check personal relevance, and move on. The better habit is confirming scope, source, and timestamp first, then reading this alongside related notices instead of drawing a conclusion from one record alone.

The original agency source is linked below so you can verify this record directly before acting on it. Its related labels are recall, product-safety, fda, drugs.

What Happened

Apollo Care, LLC initiated a recall due to the presence of particulate matter identified as nylon/polyamide and silk/proteinaceous-type material.

Which Products Are Affected

SEMAGLUTIDE 7.5mg (5mg/mL), Glycine 7.5 mg (5mg/mL), 1.5 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, NDC 71170-721-01. Lot: AC-017273, Exp. 12/12/2026. Quantity: 250 vials. Distributed nationwide within the U.S.

What You Should Do

Consumers should not use the affected product and contact the recalling firm for further instructions.

Why This Matters

This Class II recall involves a drug product distributed nationwide.

Source

FDA recall number D-0755-2026

Original source: FDA Official Notice ↗

All FDA Recalls →

Similar notices nationwide by length or severity timing 8

Two cross-category peer sets, both computed from Areazine's own archive: notices with a similar body length, and notices near the same severity and agency date. These are drawn from other categories, not the same-feed Related list above.

Common Questions

What people usually ask about a notice like this one.

What is this FDA recall about?
Apollo Care, LLC is recalling 250 vials of semaglutide 7.5mg/glycine due to particulate matter contamination.
Which agency issued this alert?
This alert was issued by FDA. The original notice is available at the source link at the bottom of this article.
How is this recall classified, and why does that matter?
The FDA classifies this as a Class II recall, citing "Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material" as the reason. Class I is the most serious (reasonable probability of serious harm), Class II is a moderate or temporary health risk, and Class III is unlikely to cause harm.
What area is affected?
This alert affects United States. Check with FDA for the most current geographic scope.
Where can I find more FDA Recalls updates?
Browse the full FDA Recalls feed on Areazine at areazine.com/recalls/fda/ for the latest updates from FDA and other agencies.